Epidemiology and Risk Factors of Uterine Fibroids in China
1 other identifier
observational
20,000
0 countries
N/A
Brief Summary
Uterine fibroids are the most common form of benign uterine tumors in the uterine muscle layer, which had a certain rate of malignancy, but it is rare. The prevalence of uterine fibroids estimates range from 4.5% to 68.6% depending on study population and diagnostic methodology. The prevalence of fibroids has been historically underestimated by epidemiologic studies which focused mainly on symptomatic women, leaving behind a large population of asymptomatic women and women who underreport their symptoms. What investigators don't know was which women who have fibroids will develop clinical symptoms and which women who have an operation of myomectomy will relapse. The purpose of this study is to investigate the prevalence, incidence and risk factors for the development of uterine fibroids in Chinese women.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2023
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 21, 2023
CompletedFirst Posted
Study publicly available on registry
May 3, 2023
CompletedStudy Start
First participant enrolled
June 19, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
ExpectedJune 22, 2023
June 1, 2023
2.5 years
April 21, 2023
June 20, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Prevalence of uterine fibroids in China
Prevalence of uterine fibroids in China
Baseline
Secondary Outcomes (2)
Incidence of uterine fibroids in China
Two follow-ups over a three-year period
Risk factors of development of uterine fibroids in China
Two follow-ups over a three-year period
Eligibility Criteria
This study population is women aged more than 18yrs with or without uterine fibroids from five regions of China. The study time period will conduct from May 1, 2023 - November 30, 2025 to allow for 6 months pre-index for evaluating baseline demographic and clinical characteristics and 24 months post-index, ensuring a minimum of one years follow-up.
You may qualify if:
- Current place of residence≥ 6 months;
- No serious mental illness or mental abnormality;
- Those who agree to participate in this survey and cooperate in completing the questionnaire.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Shixuan Wanglead
- Women's Hospital School Of Medicine Zhejiang Universitycollaborator
- Tongji Hospitalcollaborator
- First Affiliated Hospital, Sun Yat-Sen Universitycollaborator
- West China Hospitalcollaborator
- The Fourth Hospital of Shijiazhuangcollaborator
Related Publications (1)
Yan W, Yuan S, Zhou D, Zhang M, Yang S, Wang W, Wang S. Status and treatment of patients with uterine fibroids in hospitals in central China: a retrospective study from 2018 to 2021. BMJ Open. 2024 Jan 17;14(1):e081736. doi: 10.1136/bmjopen-2023-081736.
PMID: 38233053DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
SHIXUAN WANG, DOCTOR
Huazhong University of Science and Technology
Central Study Contacts
MINLI ZHANG, MASTER
CONTACT
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 21, 2023
First Posted
May 3, 2023
Study Start
June 19, 2023
Primary Completion
December 31, 2025
Study Completion (Estimated)
December 31, 2026
Last Updated
June 22, 2023
Record last verified: 2023-06